Crescent Biopharma

Gyre Therapeutics has successfully dosed the first volunteer in a Phase 1 clinical trial evaluating F230, a novel endothelin A receptor antagonist, for treating pulmonary arterial hypertension in China.

GlycoMimetics stockholders approved the proposed merger with Crescent Biopharma on June 5, 2025, along with all related proposals including a 1-for-100 reverse stock split.

China's NMPA has approved Gyre Therapeutics' clinical trial application to evaluate pirfenidone for treating radiation-induced lung injury and immune-related pneumonitis in cancer patients.

Gyre Therapeutics expects topline results from its Phase 3 trial of F351 for Chronic Hepatitis B-associated liver fibrosis in China during Q1 2025.

Merck is acquiring global rights to LaNova Medicines' LM-299, a bispecific antibody targeting PD-1 and VEGF, for $588 million, with potential milestone payments up to $2.7 billion.

Gyre Therapeutics reported Q3 2024 revenues of $25.5 million, a decrease from $32.0 million in Q3 2023, alongside a net income of $2.9 million.

Gyre Therapeutics completed its pivotal Phase 3 trial of F351 for chronic hepatitis B-associated liver fibrosis in China, with topline data expected in Q1 2025.

• Semaglutide, a GLP-1 receptor agonist, demonstrates improved kidney function in overweight/obese patients with albuminuric chronic kidney disease without diabetes. • Wider insurance coverage and a significant cost reduction are expected to drive changes in GLP-1 prescription and usage over the next five years. • Glycomimetics' stock surged following an acquisition agreement with Crescent Biopharma, despite a Phase II trial failure of uproleselan in acute myeloid leukemia.

Gyre Therapeutics has completed its pivotal Phase 3 trial of F351 (hydronidone) for chronic hepatitis B (CHB)-associated liver fibrosis in China.